This study demonstrated for the first time that TXL treatment protected SHRs against hypertensive renal injury by reducing the SBP, decreasing urinary albumin excretion, increasing creatinine clearance, and improving glomerulosclerosis and tubulointerstitial fibrosis. Here, TXNL1 is linked to glomerulosclerosis.